Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug437 | Autologous fat cell transplantation Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012003 | Rectal Fistula NIH | 1.00 |
| D005402 | Fistula NIH | 0.58 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a prospective interventional study on the treatment of transsphincteric fistula in ano. After abdominal or thigh liposuction, fat was injected around the fistula tract that was then transected percutaneously with a sharp cannula and fat injected between and around the cut parts. The internal opening was closed with a suture. Minimum follow up of 12 months is planed
Description: No fistula opening and no fistula related symptoms on clinical examination and with anal ultrasound at the outpatient clinic
Measure: Clinical healing of fistula in ano Time: 3 months after index operationDescription: No fistula opening and no fistula related symptoms on clinical examination and with anal ultrasound at the outpatient clinic
Measure: Clinical healing of fistula in ano Time: 12 months after index operationDescription: Possible complications linked to index operation
Measure: Postoperative complication Time: 3 months after index operationDescription: Possible complications linked to index operation
Measure: Postoperative complication Time: 12 months after index operationDescription: Incontinence or constipation after index operation that will be assessed with Wexner score ( On a scale of 0-20, with 0 = perfect continence and 20 = complete incontinence ).
Measure: Functional effects Time: 3 months after index operationDescription: Studied with a calendar with stool frequency and consistency, filled by patients for descriptive analysis
Measure: Functional effects Time: 3 months after index operationDescription: Incontinence or constipation after index operation that will be assessed with Wexner score ( On a scale of 0-20, with 0 = perfect continence and 20 = complete incontinence )
Measure: Functional effects Time: 12 months after index operationDescription: Studied with a calendar with stool frequency and consistency, filled by patients for descriptive analysis
Measure: Functional effects Time: 12 months after index operationDescription: The quantity of fat cell mixture injected per patient
Measure: Injected fat quantity Time: During index operationDescription: Pain or discomfort after the treatment, using Visual analog scale, for the first 3 weeks of the postoperative period. The scale ranges from 0 8 no pain ) to 10 ( maximum possible pain )
Measure: Visual Analog Pain Scale score Time: 3 months after index operationDescription: Pain or discomfort after the treatment, using Visual analog scale, for the first 3 weeks of the postoperative period. The scale ranges from 0 8 no pain ) to 10 ( maximum possible pain )
Measure: Visual Analog Pain Scale score Time: 12 months after index operationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports